Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
Phathom Pharmaceuticals, Inc. filed a Current Report on Form 8-K dated May 9, 2024, under Item 2.02 to announce financial results for the quarter ended March 31, 2024. The company’s common stock trades on the Nasdaq Global Select Market under the symbol PHAT.
Financial results and liquidity
The filing states that the company issued a press release announcing its quarterly financial results, but the provided filing text does not include the press release or clear values for revenue, net income or loss, cash flow, margins, debt, cash balances, liquidity, or other financial metrics.
Material changes versus the prior comparable period
The provided text does not present comparative financial data or identify material changes versus the prior-year or prior-quarter period.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are described in the provided filing text. These matters may be included in Exhibit 99.1, the referenced May 9, 2024 press release, which is not reproduced in the supplied content.
Facts investors should verify
- Review Exhibit 99.1 for reported revenue, expenses, net loss, cash flow, cash and investments, debt, and liquidity.
- Compare the quarter ended March 31, 2024 results with the prior comparable period and management’s previously stated expectations.
- Verify any updated financial guidance, commercialization plans, development milestones, financing needs, or risk disclosures in the press release and related filings.
- Note that the Form 8-K and Exhibit 99.1 are furnished under Item 2.02 and are not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.